Annual SG&A
$129.43 M
+$31.48 M+32.13%
31 December 2023
Summary:
Kiniksa Pharmaceuticals annual selling, general & administrative expenses is currently $129.43 million, with the most recent change of +$31.48 million (+32.13%) on 31 December 2023. During the last 3 years, it has risen by +$43.48 million (+50.59%). KNSA annual SG&A is now at all-time high.KNSA Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$46.40 M
+$4.00 M+9.44%
30 September 2024
Summary:
Kiniksa Pharmaceuticals quarterly selling, general & administrative expenses is currently $46.40 million, with the most recent change of +$4.00 million (+9.44%) on 30 September 2024. Over the past year, it has increased by +$9.66 million (+26.29%). KNSA quarterly SG&A is now at all-time high.KNSA Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$1.99 B
-$9.07 M-0.46%
30 September 2024
Summary:
Kiniksa Pharmaceuticals TTM selling, general & administrative expenses is currently -$1.99 billion, with the most recent change of -$9.07 million (-0.46%) on 30 September 2024. Over the past year, it has dropped by -$2.11 billion (-1634.01%). KNSA TTM SG&A is now -2081.83% below its all-time high of $164.22 million, reached on 30 September 2024.KNSA TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
KNSA Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +26.3% | -1634.0% |
| 3 y3 years | +50.6% | +104.0% | -2410.0% |
| 5 y5 years | +270.2% | +378.6% | -5778.8% |
KNSA Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +50.6% | at high | +108.8% | -1.0% | +27.4% |
| 5 y | 5 years | at high | +270.2% | at high | +446.8% | -60.4% | +27.4% |
| alltime | all time | at high | +1872.1% | at high | +2338.2% | -2081.8% | +27.4% |
Kiniksa Pharmaceuticals Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $46.40 M(+9.4%) | $164.22 M(+7.8%) |
| June 2024 | - | $42.40 M(+9.6%) | $152.28 M(+9.5%) |
| Mar 2024 | - | $38.68 M(+5.3%) | $139.06 M(+7.4%) |
| Dec 2023 | $129.43 M(+32.1%) | $36.74 M(+6.6%) | $129.43 M(+7.9%) |
| Sept 2023 | - | $34.47 M(+18.1%) | $119.90 M(+8.9%) |
| June 2023 | - | $29.18 M(+0.4%) | $110.11 M(+5.1%) |
| Mar 2023 | - | $29.05 M(+6.7%) | $104.78 M(+7.0%) |
| Dec 2022 | $97.95 M(+14.0%) | $27.21 M(+10.3%) | $97.95 M(+4.8%) |
| Sept 2022 | - | $24.68 M(+3.5%) | $93.48 M(+4.4%) |
| June 2022 | - | $23.84 M(+7.3%) | $89.56 M(+2.3%) |
| Mar 2022 | - | $22.22 M(-2.3%) | $87.57 M(+1.9%) |
| Dec 2021 | $85.95 M(+89.6%) | $22.74 M(+9.5%) | $85.95 M(+9.2%) |
| Sept 2021 | - | $20.76 M(-5.0%) | $78.71 M(+12.8%) |
| June 2021 | - | $21.85 M(+6.1%) | $69.75 M(+21.4%) |
| Mar 2021 | - | $20.60 M(+32.9%) | $57.44 M(+26.7%) |
| Dec 2020 | $45.32 M | $15.50 M(+31.4%) | $45.32 M(+14.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2020 | - | $11.80 M(+23.7%) | $39.52 M(+9.3%) |
| June 2020 | - | $9.54 M(+12.4%) | $36.15 M(+3.1%) |
| Mar 2020 | - | $8.49 M(-12.5%) | $35.05 M(+0.3%) |
| Dec 2019 | $34.96 M(+62.1%) | $9.70 M(+15.0%) | $34.96 M(+5.1%) |
| Sept 2019 | - | $8.43 M(-0.1%) | $33.28 M(+9.6%) |
| June 2019 | - | $8.44 M(+0.6%) | $30.36 M(+15.7%) |
| Mar 2019 | - | $8.39 M(+4.8%) | $26.25 M(+21.7%) |
| Dec 2018 | $21.56 M(+138.4%) | $8.01 M(+45.3%) | $21.57 M(+32.0%) |
| Sept 2018 | - | $5.51 M(+27.5%) | $16.33 M(+25.1%) |
| June 2018 | - | $4.33 M(+16.6%) | $13.06 M(+20.3%) |
| Mar 2018 | - | $3.71 M(+33.5%) | $10.85 M(+20.0%) |
| Dec 2017 | $9.04 M(+37.8%) | $2.78 M(+24.1%) | $9.04 M(+44.4%) |
| Sept 2017 | - | $2.24 M(+5.7%) | $6.26 M(+55.7%) |
| June 2017 | - | $2.12 M(+11.4%) | $4.02 M(+111.4%) |
| Mar 2017 | - | $1.90 M | $1.90 M |
| Dec 2016 | $6.56 M | - | - |
FAQ
- What is Kiniksa Pharmaceuticals annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Kiniksa Pharmaceuticals?
- What is Kiniksa Pharmaceuticals quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Kiniksa Pharmaceuticals?
- What is Kiniksa Pharmaceuticals quarterly SG&A year-on-year change?
- What is Kiniksa Pharmaceuticals TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Kiniksa Pharmaceuticals?
- What is Kiniksa Pharmaceuticals TTM SG&A year-on-year change?
What is Kiniksa Pharmaceuticals annual selling, general & administrative expenses?
The current annual SG&A of KNSA is $129.43 M
What is the all time high annual SG&A for Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals all-time high annual selling, general & administrative expenses is $129.43 M
What is Kiniksa Pharmaceuticals quarterly selling, general & administrative expenses?
The current quarterly SG&A of KNSA is $46.40 M
What is the all time high quarterly SG&A for Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals all-time high quarterly selling, general & administrative expenses is $46.40 M
What is Kiniksa Pharmaceuticals quarterly SG&A year-on-year change?
Over the past year, KNSA quarterly selling, general & administrative expenses has changed by +$9.66 M (+26.29%)
What is Kiniksa Pharmaceuticals TTM selling, general & administrative expenses?
The current TTM SG&A of KNSA is -$1.99 B
What is the all time high TTM SG&A for Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals all-time high TTM selling, general & administrative expenses is $164.22 M
What is Kiniksa Pharmaceuticals TTM SG&A year-on-year change?
Over the past year, KNSA TTM selling, general & administrative expenses has changed by -$2.11 B (-1634.01%)